Natixis Poseida Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding PSTX
# of Institutions
98Shares Held
38.5MCall Options Held
377KPut Options Held
22.2K-
Pentwater Capital Management LP Naples, FL5.98MShares$56.4 Million0.18% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$46.3 Million0.0% of portfolio
-
Silverarc Capital Management, LLC3.69MShares$34.8 Million2.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.66MShares$34.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$20.7 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $810M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...